Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Successful Conversion Rate of Operation 1Sarcoma 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasms 1Mouth Neoplasms 1Head and Neck Neoplasms 1Desmoplastic Small Round Cell Tumor 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 3atezolizumab 2trametinib 1sargramostim 1ruxolitinib 1reolysin 1poly(I).poly(c12,U) 1poly ICLC 1neratinib 1incomplete Freund's adjuvant 1glembatumumab vedotin 1epigallocatechin gallate 1entinostat 1dupilumab 1Zymosan 1Zinc 1Watchful Waiting 1Vaccines 1Uridine Monophosphate 1Trastuzumab 1Technetium Tc 99m Sestamibi 1Taxes 1Quercetin 1Positron-Emission Tomography 1Paclitaxel 1Neurofibromin 2 1Neoadjuvant Therapy 1Metformin 1Leukapheresis 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Triple Negative Breast Neoplasms × Neoadjuvant Therapy × Clear all
NCT05333874 2026-02-09

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Active not recruiting
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡